Novartis to expand cancer treatments with $1.5B investment

Novartis, the Swiss pharmaceutical company, has acquired the British biotechnology firm Myriex Bio for $1.5 billion, aiming to strengthen its presence in the cancer treatment market and expand its research platform. The company specializes in developing antibody-drug conjugates that target the delivery of therapy directly to cancer cells, a rapidly growing area in tumor research. The deal is expected to be completed in the second half of 2026 after meeting regulatory requirements.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل